ENOblockAntibodies will be the leading class of therapeutics, due in large part to their capability to interact with distinctive ligand conformations so that you can elicit particular biological responses. Even so, discovery of latest molecules binding certain epitopes is time intensive and challenging, especially for situations requiring a particu